SEO URLwww.firestrike.ai/deals/gsk-samsung-biologics-acquisition-2026
acquisitionAnnounced · Jan 8, 2026BiopharmaceuticalsSource · CredibleArticle · Factual
SAMSUNG BIOLOGICS acquires GSK
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$280M
Target
GSK
NYSE: GSK · London, Greater London
Acquirer
SAMSUNG BIOLOGICS
Full Acquisition
Status
Completed
SAMSUNG BIOLOGICS agreed to acquire GSK. Reported deal value: $280M. Status: Completed. Sector: Biopharmaceuticals. Target headquarters context: London, Greater London, United Kingdom.
This page summarizes publicly available information about the transaction as of 2026-01-08. Figures and status may change as filings and press coverage update.
Copy Link Samsung Biologics has entered the US manufacturing market for the first time, acquiring a biopharmaceutical production facility in Maryland from GlaxoSmithKline in a deal valued at $ 28 0m
Deal timeline
Announced
Jan 8, 2026 · themanufacturer.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biopharmaceuticals with a reported deal value of $280M. Figures and status may change as sources update.
Sources: themanufacturer.com · Primary article · FireStrike proprietary index